

1 Supplemental Table 1: Comparison of the clinical sensitivity for the detection of CIN2+ and
 2 CIN3+ with clinical specificity for ≤CIN1 of Anyplex, hc2, and cobas in women < 30 years old.

Test	Clinical sensitivity for CIN2+ (%)	Clinical sensitivity for CIN3+ (%)	Clinical specificity (%)
Anyplex	96.6% (28/29; 95 CI, 82.2-99.9)	100% (16/16; 95 CI, 79.4-100)	78.8% (160/203; 95% CI, 72.5-84.2)
hc2	96.6% (28/29; 95 CI, 82.2-99.9)	100% (16/16; 95 CI, 79.4-100)	77.3% (157/203; 95 CI, 71.0-82.9)
Cobas	93.1% (27/29; 95 CI, 77.2-99.2)	100% (16/16; 95 CI, 79.4-100)	78.7% (159/202; 95 CI, 72.4-84.1)

4 Supplemental Table 2: Relative sensitivity and specificity of Anyplex compared to i) hc2 and ii)
 5 cobas in women <30 years old.

	Clinical outcome	Relative sensitivity	Relative specificity	p_{McN}^a	p_{Ni}^b
Anyplex vs. hc2	CIN2+	1.00 (0.90-1.11) ^c		1.000	0.039
	CIN3+	1.00 (0.86-1.17) ^c		1.000	0.091
	\leq CIN1		1.02 (0.98-1.06)	0.5087	0.029
Anyplex vs. cobas	CIN2+	1.04 (0.97-1.11) ^c		1.000	0.010
	CIN3+	1.00 (0.86-1.17) ^c		1.000	0.091
	\leq CIN1		1.00 (0.96-1.04)	1.000	0.165

6 Abbreviations: ^a p_{McN} = p value for McNemar test; ^b p_{Ni} = p value in non-inferiority testing;

7 ^cconfidence interval calculated with Nam-Blackwelder interval due to zero non-matched cases.